Irofulven + Prednisone + Mitoxantrone + Capecitabine + Irofulven
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
Jun 1, 2004 → Dec 1, 2009
NCT ID
NCT00124566About Irofulven + Prednisone + Mitoxantrone + Capecitabine + Irofulven
Irofulven + Prednisone + Mitoxantrone + Capecitabine + Irofulven is a phase 2 stage product being developed by Eisai for Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00124566. Target conditions include Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00124566 | Phase 2 | Completed |
Competing Products
20 competing products in Prostate Cancer